Cells as delivery vehicles for cancer therapeutics

Therapeutic Delivery

Volumn 5, Issue 5, 2014, Pages 555-567

  Basel, Matthew T ^a   Shrestha, Tej B ^a   Bossmann, Stefan H ^a   Troyer, Deryl L ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL TYPE; DRUG DELIVERY SYSTEM; HUMAN; MESENCHYMAL STEM CELL; MONOCYTE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MESENCHYMAL STROMAL CELLS; MONOCYTES; NEOPLASMS; NEURAL STEM CELLS;

EID: 84903991277     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.24     Document Type: Review

References (103)

1. Fischbach MA, Bluestone JA, Lim WA. Cell-based therapeutics: the next pillar of medicine, Sci. Transl. Med. 5 (179), ps7 (2013).
2. Stem Cell Therapeutics for Cancer. Shah K (Ed.) John Wiley & Sons, Inc., Hoboken, NJ, USA (2013).
3. Lin G, Yang R, Banie L et al. Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. Prostate 70(10), 1066-1073 (2010).
4. Shinojima N, Hossain A, Takezaki T et al. TGF-beta mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells. Cancer Res. 73(7), 2333-2344 (2013).
5. Aboody KS, Brown A, Rainov NG et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl Acad. Sci. USA 97(23), 12846-12851 (2000).
6. Aboody KS, Bush RA, Garcia E et al. Development of a tumor-selective approach to treat metastatic cancer. PLoS ONE 1, e23 (2006).
7. Shimato S, Natsume A, Takeuchi H et al. Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal medulloblastoma. Gene Ther. 14(15), 1132-1142 (2007).
8. Wang C, Natsume A, Lee HJ et al. Neural stem cell-based dual suicide gene delivery for metastatic brain tumors. Cancer Gene Ther. 19(11), 796-801 (2012).
9. Bovenberg MS, Degeling MH, Tannous BA. Advances in stem cell therapy against gliomas. Trends Mol. Med. 19(5), 281-291 (2013).
10. Reitz M, Demestre M, Sedlacik J et al. Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma. Stem Cells Transl. Med. 1(12), 866-873 (2012).
11. Gerecht-Nir S, Itskovitz-Eldor J. Human embryonic stem cells: a potential source for cellular therapy. Am. J. Transplant. 4(Suppl. 6), 51-57 (2004).
12. Balyasnikova IV, Ferguson SD, Han Y, Liu F, Lesniak MS. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer Lett. 310(2), 148-159 (2011).
13. Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res. 71(1), 154-163 (2011).
14. Van De Water JA, Bagci-Onder T, Agarwal AS et al. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proc. Natl Acad. Sci. USA 109(41), 16642-16647 (2012).
15. Frank RT, Edmiston M, Kendall SE et al. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS ONE 4(12), e8314 (2009).
16. Thaci B, Ahmed AU, Ulasov IV et al. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther. 19(6), 431-442 (2012).
17. Ahmed AU, Thaci B, Alexiades NG et al. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol. Ther. 19(9), 1714-1726 (2011).
18. Ahmed AU, Tyler MA, Thaci B et al. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol. Pharm. 8(5), 1559-1572 (2011).
19. Tobias AL, Thaci B, Auffinger B et al. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma. Stem Cells Transl. Med. 2(9), 655-666 (2013).
20. Schnarr K, Mooney R, Weng Y et al. Gold nanoparticle-loaded neural stem cells for photothermal ablation of cancer. Adv. Healthc. Mater. 2(7), 976-982 (2013).
21. Rachakatla RS, Balivada S, Seo GM et al. Attenuation of mouse melanoma by A/C magnetic field after delivery of bi-magnetic nanoparticles by neural progenitor cells. ACS Nano 4(12), 7093-7104 (2010).
22. Ring KL, Tong LM, Balestra ME et al. Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell 11(1), 100-109 (2012).
23. Yang J, Lam DH, Goh SS et al. Tumor tropism of intravenously injected human-induced pluripotent stem cell-derived neural stem cells and their gene therapy application in a metastatic breast cancer model. Stem Cells 30(5), 1021-1029 (2012).
24. Chen C, Wang Y, Goh SS et al. Inhibition of neuronal nitric oxide synthase activity promotes migration of human-induced pluripotent stem cell-derived neural stem cells toward cancer cells. J. Neurochem. 126(3), 318-330 (2013).
25. City of Hope Medical Center. A pilot feasibility study of oral 5-fluorocytosine and genetically-modified neural stem cells expressing E. coli cytosine deaminase for treatment of recurrent high grade gliomas. NCT011729642010. www.clinicaltrials.gov/show/NCT01172964
26. Hori J, Ng TF, Shatos M, Klassen H, Streilein JW, Young MJ. Neural progenitor cells lack immunogenicity and resist destruction as allografts. Stem Cells 21(4), 405-416 (2003).
27. Michel-Monigadon D, Brachet P, Neveu I, Naveilhan P. Immunoregulatory properties of neural stem cells. Immunotherapy 3(Suppl. 4), 39-41 (2011).
28. Xie J, Zhang H, Yea K, Lerner RA. Autocrine signaling based selection of combinatorial antibodies that transdifferentiate human stem cells. Proc. Natl Acad. Sci. USA 110(20), 8099-8104 (2013).
29. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 62(13), 3603-3608 (2002).
30. Altaner C. Prodrug cancer gene therapy. Cancer Lett. 270(2), 191-201 (2008).
31. Cihova M, Altanerova V, Altaner C. Stem cell based cancer gene therapy. Mol. Pharm. 8(5), 1480-1487 (2011).
32. Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol. Cancer 9, 129 (2010).
33. Rachakatla RS, Marini F, Weiss ML, Tamura M, Troyer D. Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther. 14(10), 828-835 (2007).
34. Rachakatla RS, Pyle MM, Ayuzawa R et al. Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs. Cancer Invest. 26(7), 662-670 (2008).
35. Ganta C, Chiyo D, Ayuzawa R et al. Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. Cancer Res. 69(5), 1815-1820 (2009).
36. Wang M, Yang Y, Yang D et al. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Immunology 126(2), 220-232 (2009).
37. Nakamizo A, Marini F, Amano T et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 65(8), 3307-3318 (2005).
38. Zou W, Zheng H, He TC, Chang J, Fu YX, Fan W. LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response. Cancer Res. 72(12), 2980-2989 (2012).
39. Zhu X, Su D, Xuan S et al. Gene therapy of gastric cancer using LIGHT-secreting human umbilical cord blood-derived mesenchymal stem cells. Gastric Cancer 16(2), 155-166 (2013).
40. Mader EK, Maeyama Y, Lin Y et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin. Cancer Res. 15(23), 7246-7255 (2009).
41. Russell SJ, Peng KW. The utility of cells as vehicles for oncolytic virus therapies. Curr. Opin. Mol. Ther. 10(4), 380-386 (2008).
42. Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 26(3), 831-841 (2008).
43. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther. 5(3), 755-766 (2006).
44. Roger M, Clavreul A, Venier-Julienne MC et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials 31(32), 8393-8401 (2010).
45. Roger M, Clavreul A, Huynh NT et al. Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. Int. J. Pharm. 423(1), 63-68 (2012).
46. Dembinski JL, Wilson SM, Spaeth EL et al. Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. Cytotherapy 15(1), 20-32 (2013).
47. Altanerova V, Cihova M, Babic M et al. Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase:uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma. Int. J. Cancer 130(10), 2455-2463 (2012).
48. Cavarretta IT, Altanerova V, Matuskova M, Kucerova L, Culig Z, Altaner C. Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol. Ther. 18(1), 223-231 (2010).
49. Kucerova L, Matuskova M, Pastorakova A et al. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J. Gene Med. 10(10), 1071-1082 (2008).
50. Altaner C, Altanerova V, Cihova M et al. Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario. Int. J. Cancer 134(6), 1458-1465 (2014).
51. Grisendi G, Bussolari R, Cafarelli L et al. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 70(9), 3718-3729 (2010).
52. Khakoo AY, Pati S, Anderson SA et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med. 203(5), 1235-1247 (2006).
53. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F 3rd. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 29(1), 11-19 (2011).
54. Kidd S, Spaeth E, Watson K et al. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS ONE 7(2), e30563 (2012).
55. Mishra PJ, Humeniuk R, Medina DJ et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 68(11), 4331-4339 (2008).
56. Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells 30(2), 266-279 (2012).
57. Li X, Ling W, Khan S, Yaccoby S et al. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. J. Bone Miner. Res. 27(8), 1635-1648 (2012).
58. Lamfers M, Idema S, Van Milligen F et al. Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection. Cancer Lett. 274(1), 78-87 (2009).
59. Lee WY, Zhang T, Lau CP, Wang CC, Chan KM, Li G. Immortalized human fetal bone marrow-derived mesenchymal stromal cell expressing suicide gene for anti-tumor therapy in vitro and in vivo. Cytotherapy 15(12), 1484-1497 (2013).
60. Roemeling-Van Rhijn M, De Klein A, Douben H. Culture expansion induces non-tumorigenic aneuploidy in adipose tissue-derived mesenchymal stromal cells. Cytotherapy 15(11), 1352-1361 (2013).
61. Becker M, Muller CB, De Bastiani MA, Klamt F. The prognostic impact of tumor-associated macrophages and intra-tumoral apoptosis in non-small cell lung cancer. Histol. Histopathol. 29(1), 21-31 (2013).
62. Chimal-Ramirez GK, Espinoza-Sanchez NA, Fuentes- Panana EM et al. Protumor activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion. J. Oncol. 2013, 835956 (2013).
63. Partecke LI, Gunther C, Hagemann S et al. Induction of M2-macrophages by tumour cells and tumour growth promotion by M2-macrophages: a quid pro quo in pancreatic cancer. Pancreatology 13(5), 508-516 (2013).
64. Baron-Bodo V, Doceur P, Lefebvre ML et al. Anti-tumor properties of human-activated macrophages produced in large scale for clinical application. Immunobiology 210(2-4), 267-277 (2005).
65. Chen W, Liu J, Meng J et al. Macrophage polarization induced by neuropeptide methionine enkephalin (MENK) promotes tumoricidal responses. Cancer Immunol. Immunother. 61(10), 1755-1768 (2012).
66. Nguyen HY, Vo BH, Nguyen LT et al. Extracts of Crinum latifolium inhibit the cell viability of mouse lymphoma cell line EL4 and induce activation of anti-tumour activity of macrophages in vitro. J. Ethnopharmacol. 149(1), 75-83 (2013).
67. Rey-Giraud F, Hafner M, Ries CH et al. In vitro generation of monocyte-derived macrophages under serum-free conditions improves their tumor promoting functions. PLoS ONE 7(8), e42656 (2012).
68. De Palma M, Venneri MA, Galli R et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3), 211-226 (2005).
69. Du R, Lu KV, Petritsch C et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13(3), 206-220 (2008).
70. De Palma M, Naldini L. Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy? Biochim. Biophys. Acta 1796(1), 5-10 (2009).
71. De Palma M, Mazzieri R, Politi LS et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14(4), 299-311 (2008).
72. Russell JS, Brown JM. The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. Front. Physiol. 4, 157 (2013).
73. Skivka LM, Gorobets OB, Kutsenok VV et al. 5-aminolevulinic acid mediated photodynamic therapy of Lewis lung carcinoma: a role of tumor infiltration with different cells of immune system. Exp. Oncol. 26(4), 312-315 (2004).
74. Brugger W, Bross K, Frisch J et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 79(5), 1193-1200 (1992).
75. Krosl G, Korbelik M, Dougherty GJ et al. Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. Br. J. Cancer 71(3), 549-555 (1995).
76. Ma Y, Adjemian S, Mattarollo SR et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38(4), 729-741 (2013).
77. Schioppa T, Uranchimeg B, Saccani A et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med. 198(9), 1391-1402 (2003).
78. Kean TJ, Duesler L, Young RG et al. Development of a peptide-targeted, myocardial ischemia-homing, mesenchymal stem cell. J. Drug Target. 20(1), 23-32 (2012).
79. Sharma A, Kapoor P, Gautam A et al. Computational approach for designing tumor homing peptides. Sci. Rep. 3, 1607 (2013).
80. Muthana M, Scott SD, Farrow N et al. A novel magnetic approach to enhance the efficacy of cell-based gene therapies. Gene Ther. 15(12), 902-910 (2008).
81. Choi MR, Stanton-Maxey KJ, Stanley JK et al. A cellular Trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 7(12), 3759-3765 (2007).
82. Baek SK, Makkouk AR, Krasieva T, Sun CH, Madsen SJ, Hirschberg H. Photothermal treatment of glioma; an in vitro study of macrophage-mediated delivery of gold nanoshells. J. Neurooncol. 104(2), 439-448 (2011).
83. Basel MT, Balivada S, Wang H et al. Cell-delivered magnetic nanoparticles caused hyperthermia-mediated increased survival in a murine pancreatic cancer model. Int. J. Nanomedicine 7, 297-306 (2012).
84. Seo GM, Rachakatla RS, Balivada S et al. A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma. Mol. Biol. Rep. 39(1), 157-165 (2012).
85. Basel MT, Balivada S, Shrestha TB et al. A cell-delivered and cell-activated SN38-dextran prodrug increases survival in a murine disseminated pancreatic cancer model. Small 8(6), 913-920 (2012).
86. Bunuales M, Garcia-Aragoncillo E, Casado R et al. Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer. Hum. Gene Ther. 23(12), 1258-1268 (2012).
87. Muthana M, Giannoudis A, Scott SD et al. Use of macrophages to target therapeutic adenovirus to human prostate tumors. Cancer Res. 71(5), 1805-1815 (2011).
88. Choi MR, Bardhan R, Stanton-Maxey KJ et al. Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. Cancer Nanotechnol. 3(1-6), 47-54 (2012).
89. Matsui M, Shimizu Y, Kodera Y, Kondo E, Ikehara Y, Nakanishi H. Targeted delivery of oligomannose-coated liposome to the omental micrometastasis by peritoneal macrophages from patients with gastric cancer. Cancer Sci. 101(7), 1670-1677 (2010).
90. Choi J, Kim HY, Ju EJ et al. Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials 33(16), 4195-4203 (2012).
91. Batrakova EV, Li S, Reynolds AD et al. A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug. Chem. 18(5), 1498-1506 (2007).
92. Gonzalez-Mejia ME, Doseff AI. Regulation of monocytes and macrophages cell fate. Front. Biosci. (Landmark Ed.) 14, 2413-2431 (2009).
93. Zhang JX, Kang CS, Shi L, Zhao P, Liu N, You YP. Use of thymidine kinase gene-modified endothelial progenitor cells as a vector targeting angiogenesis in glioma gene therapy. Oncology 78(2), 94-102 (2010).
94. Eisenstein S, Coakley BA, Briley-Saebo K et al. Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res. 73(16), 5003-5015 (2013).
95. Becker ML, Near R, Mudgett-Hunter M et al. Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. Cell 58(5), 911-921 (1989).
96. Kuwana Y, Asakura Y, Utsunomiya N et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem. Biophys. Res. Commun. 149(3), 960-968 (1987).
97. Gross G, Gorochov G, Waks T, Eshhar Z. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant. Proc. 21(1 Pt 1), 127-130 (1989).
98. Gross G, Waks T, Eshhar Z et al. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86(24), 10024-10028 (1989).
99. Milone MC, Fish JD, Carpenito C et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17(8), 1453-1464 (2009).
100. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3(95), 95ra73 (2011).
101. Song DG, Ye Q, Carpenito C et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71(13), 4617-4627 (2011).
102. Brentjens RJ, Riviere I, Park JH et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118(18), 4817-4828 (2011).
103. Hudecek M, Schmitt TM, Baskar S et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116(22), 4532-4541 (2010).